From the Research
Tofacitinib is not approved for use in children, and its safety and efficacy in pediatric populations have not been established. The provided evidence does not discuss the use of Tofacitinib in children, but rather focuses on the risks associated with codeine use in pediatric populations 1, 2, 3, 4, 5.
Key Considerations
- The evidence provided does not address the use of Tofacitinib in children, and therefore, it is not possible to recommend a dose for pediatric use.
- Tofacitinib is a medication that is typically used to treat certain adult conditions, such as rheumatoid arthritis, and its use in children is not supported by the available evidence.
- The safety and efficacy of Tofacitinib in pediatric populations have not been established, and its use in children may pose potential risks.
Recommendations
- Tofacitinib should not be used in children due to the lack of safety and efficacy data.
- Pediatric patients should be treated with alternative therapies that have established safety and efficacy profiles in children.
- Healthcare providers should exercise caution when prescribing medications to children and carefully consider the potential risks and benefits of each treatment option.